Reposted by Amir Hasan
Dr. Masri from #ACC.25. Responders analysis - acoramidis vs placebo for improving NYHA class from the ATTRibute-CM. #ACC25 #CardioSky #Cardiology
March 31, 2025 at 4:32 PM
Dr. Masri from #ACC.25. Responders analysis - acoramidis vs placebo for improving NYHA class from the ATTRibute-CM. #ACC25 #CardioSky #Cardiology
Reposted by Amir Hasan
ASE experts connect with industry partners to drive advances in the field like #Strain, #3DEcho, and #ArtificialIntelligence while focusing on disease diagnosis in #HCM, #Amyloidosis, #ValveDisease, and more!
#ASEIRT #PartnersInInnovation #HeartofASE #ASEMemberDay #EchoFirst
#ASEIRT #PartnersInInnovation #HeartofASE #ASEMemberDay #EchoFirst
March 28, 2025 at 5:00 PM
ASE experts connect with industry partners to drive advances in the field like #Strain, #3DEcho, and #ArtificialIntelligence while focusing on disease diagnosis in #HCM, #Amyloidosis, #ValveDisease, and more!
#ASEIRT #PartnersInInnovation #HeartofASE #ASEMemberDay #EchoFirst
#ASEIRT #PartnersInInnovation #HeartofASE #ASEMemberDay #EchoFirst
Reposted by Amir Hasan
The pivotal ATTR-ACT trial showed tafamadis ⬇️ mort rates in patients w/ATTR-CM. What about real world data?
🌍THOAS data confirms the mort benefit w/⬆️ survival rates compared to ATTR-ACT trial. Early diagnosis and treatment is 🔑 in amyloid CM 🫀
🔗 bit.ly/4imXPCw
🌍THOAS data confirms the mort benefit w/⬆️ survival rates compared to ATTR-ACT trial. Early diagnosis and treatment is 🔑 in amyloid CM 🫀
🔗 bit.ly/4imXPCw
March 18, 2025 at 5:32 PM
The pivotal ATTR-ACT trial showed tafamadis ⬇️ mort rates in patients w/ATTR-CM. What about real world data?
🌍THOAS data confirms the mort benefit w/⬆️ survival rates compared to ATTR-ACT trial. Early diagnosis and treatment is 🔑 in amyloid CM 🫀
🔗 bit.ly/4imXPCw
🌍THOAS data confirms the mort benefit w/⬆️ survival rates compared to ATTR-ACT trial. Early diagnosis and treatment is 🔑 in amyloid CM 🫀
🔗 bit.ly/4imXPCw
New ATTR-CM therapies shine: Pfizer’s Tafamidis cuts mortality 13%, Alnylam’s Vutrisiran slashes CV events 28%, Ionis/AstraZeneca’s Eplontersen in trials, BridgeBio’s Acoramidis boosts survival to 81%. Early Dx is key—EchoGo’s AI interprets echos to spot it fast. CRISPR looms big! @ultromics.com
March 10, 2025 at 9:18 PM
New ATTR-CM therapies shine: Pfizer’s Tafamidis cuts mortality 13%, Alnylam’s Vutrisiran slashes CV events 28%, Ionis/AstraZeneca’s Eplontersen in trials, BridgeBio’s Acoramidis boosts survival to 81%. Early Dx is key—EchoGo’s AI interprets echos to spot it fast. CRISPR looms big! @ultromics.com
Reposted by Amir Hasan
🧠 Can Imaging Be a Surrogate Endpoint in Amyloidosis Trials?
A recent JACC:CVI review by Dorbala et al. highlights the role of imaging biomarkers in clinical trials for amyloidosis.
www.jacc.org/doi/abs/10.1...
A recent JACC:CVI review by Dorbala et al. highlights the role of imaging biomarkers in clinical trials for amyloidosis.
www.jacc.org/doi/abs/10.1...
March 10, 2025 at 4:38 PM
🧠 Can Imaging Be a Surrogate Endpoint in Amyloidosis Trials?
A recent JACC:CVI review by Dorbala et al. highlights the role of imaging biomarkers in clinical trials for amyloidosis.
www.jacc.org/doi/abs/10.1...
A recent JACC:CVI review by Dorbala et al. highlights the role of imaging biomarkers in clinical trials for amyloidosis.
www.jacc.org/doi/abs/10.1...
Reposted by Amir Hasan
#HeartMonth is a great time to get a cardiac risk assessment & know if you are at risk for heart disease. 80% of heart disease is preventable but we don’t often screen women. Heart disease is the #1 killer of women. Lack of awareness is a close second.
#GoRedforWomen #CVPrev #CardioSky
#GoRedforWomen #CVPrev #CardioSky
February 3, 2025 at 9:38 PM
#HeartMonth is a great time to get a cardiac risk assessment & know if you are at risk for heart disease. 80% of heart disease is preventable but we don’t often screen women. Heart disease is the #1 killer of women. Lack of awareness is a close second.
#GoRedforWomen #CVPrev #CardioSky
#GoRedforWomen #CVPrev #CardioSky
Reposted by Amir Hasan
Heart disease in women is far too often misdiagnosed or dismissed
A (not so) shocking 84% of female cardiologists surveyed reported treating women whose symptoms were ignored or misdiagnosed
This is disgraceful. Advocate for better awareness.
#CVprev #Cardiosky
#HeartAndSoul
A (not so) shocking 84% of female cardiologists surveyed reported treating women whose symptoms were ignored or misdiagnosed
This is disgraceful. Advocate for better awareness.
#CVprev #Cardiosky
#HeartAndSoul
February 4, 2025 at 12:31 AM
Heart disease in women is far too often misdiagnosed or dismissed
A (not so) shocking 84% of female cardiologists surveyed reported treating women whose symptoms were ignored or misdiagnosed
This is disgraceful. Advocate for better awareness.
#CVprev #Cardiosky
#HeartAndSoul
A (not so) shocking 84% of female cardiologists surveyed reported treating women whose symptoms were ignored or misdiagnosed
This is disgraceful. Advocate for better awareness.
#CVprev #Cardiosky
#HeartAndSoul
Reposted by Amir Hasan
EchoGo® Heart Failure was developed with Mayo Clinic.
Patricia A. Pellikka, MD shares her views on the impact of our AI platform in detecting heart failure patients. Learn more about how EchoGo® Heart Failure supports #HeartFailure detection: www.ultromics.com/products/ech... #CardioSky #MedSky
Patricia A. Pellikka, MD shares her views on the impact of our AI platform in detecting heart failure patients. Learn more about how EchoGo® Heart Failure supports #HeartFailure detection: www.ultromics.com/products/ech... #CardioSky #MedSky
January 31, 2025 at 6:05 PM
EchoGo® Heart Failure was developed with Mayo Clinic.
Patricia A. Pellikka, MD shares her views on the impact of our AI platform in detecting heart failure patients. Learn more about how EchoGo® Heart Failure supports #HeartFailure detection: www.ultromics.com/products/ech... #CardioSky #MedSky
Patricia A. Pellikka, MD shares her views on the impact of our AI platform in detecting heart failure patients. Learn more about how EchoGo® Heart Failure supports #HeartFailure detection: www.ultromics.com/products/ech... #CardioSky #MedSky
Reposted by Amir Hasan
EchoGo® Amyloidosis is the first AI screening tool to help detect Cardiac #Amyloidosis using #EchoFirst. Seamlessly integrating into clinical workflows, it supports timely identification and intervention. 👉 www.ultromics.com/products/ech... #MedSky #CardioSky
January 28, 2025 at 4:08 PM
EchoGo® Amyloidosis is the first AI screening tool to help detect Cardiac #Amyloidosis using #EchoFirst. Seamlessly integrating into clinical workflows, it supports timely identification and intervention. 👉 www.ultromics.com/products/ech... #MedSky #CardioSky
Reposted by Amir Hasan
Welcome immigrants from X interested in science to the friendlier skies of @bsky.app, as documented by a new @nature.com survey (but you already knew that 😉)
"Bluesky is much better for science. There is much less toxicity, misinformation, and distractions."
www.nature.com/articles/d41...
"Bluesky is much better for science. There is much less toxicity, misinformation, and distractions."
www.nature.com/articles/d41...
January 24, 2025 at 3:22 PM
Welcome immigrants from X interested in science to the friendlier skies of @bsky.app, as documented by a new @nature.com survey (but you already knew that 😉)
"Bluesky is much better for science. There is much less toxicity, misinformation, and distractions."
www.nature.com/articles/d41...
"Bluesky is much better for science. There is much less toxicity, misinformation, and distractions."
www.nature.com/articles/d41...
Reposted by Amir Hasan
In the European Heart Journal, we report a novel paradigm for predicting HF risk.
AI applied to a single ECG image. Without risk scores or other testing.
Led by @lovedeepdhingra.bsky.social @cardslab.bsky.social
@yaleschoolofmed.bsky.social
🔗 academic.oup.com/eurheartj/ad...
AI applied to a single ECG image. Without risk scores or other testing.
Led by @lovedeepdhingra.bsky.social @cardslab.bsky.social
@yaleschoolofmed.bsky.social
🔗 academic.oup.com/eurheartj/ad...
January 24, 2025 at 4:43 PM
In the European Heart Journal, we report a novel paradigm for predicting HF risk.
AI applied to a single ECG image. Without risk scores or other testing.
Led by @lovedeepdhingra.bsky.social @cardslab.bsky.social
@yaleschoolofmed.bsky.social
🔗 academic.oup.com/eurheartj/ad...
AI applied to a single ECG image. Without risk scores or other testing.
Led by @lovedeepdhingra.bsky.social @cardslab.bsky.social
@yaleschoolofmed.bsky.social
🔗 academic.oup.com/eurheartj/ad...
Reposted by Amir Hasan
Reposted by Amir Hasan
❓ Test your knowledge:
Cardiac #Amyloidosis is challenging to diagnose, often requiring a high degree of clinical suspicion. Early recognition of red flags, including non-cardiac indicators, is critical for timely diagnosis and effective treatment. #CardioSky #MedSky
Cardiac #Amyloidosis is challenging to diagnose, often requiring a high degree of clinical suspicion. Early recognition of red flags, including non-cardiac indicators, is critical for timely diagnosis and effective treatment. #CardioSky #MedSky
January 24, 2025 at 1:35 PM
❓ Test your knowledge:
Cardiac #Amyloidosis is challenging to diagnose, often requiring a high degree of clinical suspicion. Early recognition of red flags, including non-cardiac indicators, is critical for timely diagnosis and effective treatment. #CardioSky #MedSky
Cardiac #Amyloidosis is challenging to diagnose, often requiring a high degree of clinical suspicion. Early recognition of red flags, including non-cardiac indicators, is critical for timely diagnosis and effective treatment. #CardioSky #MedSky
Reposted by Amir Hasan
We’re excited to share our latest research & innovation at several events this year. Ultromics is transforming cardiology with advanced AI that supports #HFpEF and Cardiac #Amyloidosis detection. Upcoming events: www.ultromics.com/about/events #EchoGo #MedSky #CardioSky
January 14, 2025 at 2:21 PM
We’re excited to share our latest research & innovation at several events this year. Ultromics is transforming cardiology with advanced AI that supports #HFpEF and Cardiac #Amyloidosis detection. Upcoming events: www.ultromics.com/about/events #EchoGo #MedSky #CardioSky
Reposted by Amir Hasan
Detecting HFpEF early is critical so patients can benefit from these innovative treatments. #SGLT2 inhibitors are a breakthrough treatment for HFpEF. However, many patients are undiagnosed. EchoGo® Heart Failure uses advanced AI to detect #HFpEF from a single routine echo. Learn more: ultromics.com
#SGLT2 inhibitors are key in preventing adverse CV events & improving outcomes in patients w/ heart failure, diabetes & chronic kidney disease. Explore the updated #CardioSmart SGLT2 inhibitor package w/ an infographic, discussion guide, & more. bit.ly/3PssDFq
#CardioSky #MedSky
#CardioSky #MedSky
January 10, 2025 at 1:43 PM
Detecting HFpEF early is critical so patients can benefit from these innovative treatments. #SGLT2 inhibitors are a breakthrough treatment for HFpEF. However, many patients are undiagnosed. EchoGo® Heart Failure uses advanced AI to detect #HFpEF from a single routine echo. Learn more: ultromics.com
Reposted by Amir Hasan
EchoGo® Heart Failure is eligible for reimbursement in both inpatient & outpatient settings & includes
#HFpEF & Cardiac Amyloidosis detection to aid care in #HeartFailure.
💰 Inpatient: NTAP XXE2X19 – Up to $1,023.75
💰 Outpatient: CPT 0932T – $299.91
👉https://www.ultromics.com/about/reimbursement
#HFpEF & Cardiac Amyloidosis detection to aid care in #HeartFailure.
💰 Inpatient: NTAP XXE2X19 – Up to $1,023.75
💰 Outpatient: CPT 0932T – $299.91
👉https://www.ultromics.com/about/reimbursement
January 8, 2025 at 4:12 PM
EchoGo® Heart Failure is eligible for reimbursement in both inpatient & outpatient settings & includes
#HFpEF & Cardiac Amyloidosis detection to aid care in #HeartFailure.
💰 Inpatient: NTAP XXE2X19 – Up to $1,023.75
💰 Outpatient: CPT 0932T – $299.91
👉https://www.ultromics.com/about/reimbursement
#HFpEF & Cardiac Amyloidosis detection to aid care in #HeartFailure.
💰 Inpatient: NTAP XXE2X19 – Up to $1,023.75
💰 Outpatient: CPT 0932T – $299.91
👉https://www.ultromics.com/about/reimbursement
Reposted by Amir Hasan
Here at the #WCIRDC2024 conference where I presented in #HFpEF and sex specific considerations for women. I shared a summary of this with #HCPLive . #CardioSky #WomensHeartHealth
www.hcplive.com/view/erin-mi...
www.hcplive.com/view/erin-mi...
Erin Michos, MD: HFpEF in Women and Sex-Specific Therapeutic Approaches
Erin Michos, MD examines unique HFpEF mechanisms for women and implications for sex-specific treatment.
www.hcplive.com
December 14, 2024 at 12:43 AM
Here at the #WCIRDC2024 conference where I presented in #HFpEF and sex specific considerations for women. I shared a summary of this with #HCPLive . #CardioSky #WomensHeartHealth
www.hcplive.com/view/erin-mi...
www.hcplive.com/view/erin-mi...
Reposted by Amir Hasan
2024 was a blast in cardiovascular imaging congresses led by EACVI. Be ready for #EACVI2025:
📍Vienna
📅11-13 Dcember
👨👩👦👦#EuroeEcho, #EuroCMR and #ICNC-CT together
Help us to shape the programme and be part of it
👉https://escardio.formstack.com/forms/eacvi_2025_call_for_sessions #cardiosky
📍Vienna
📅11-13 Dcember
👨👩👦👦#EuroeEcho, #EuroCMR and #ICNC-CT together
Help us to shape the programme and be part of it
👉https://escardio.formstack.com/forms/eacvi_2025_call_for_sessions #cardiosky
December 14, 2024 at 9:56 AM
2024 was a blast in cardiovascular imaging congresses led by EACVI. Be ready for #EACVI2025:
📍Vienna
📅11-13 Dcember
👨👩👦👦#EuroeEcho, #EuroCMR and #ICNC-CT together
Help us to shape the programme and be part of it
👉https://escardio.formstack.com/forms/eacvi_2025_call_for_sessions #cardiosky
📍Vienna
📅11-13 Dcember
👨👩👦👦#EuroeEcho, #EuroCMR and #ICNC-CT together
Help us to shape the programme and be part of it
👉https://escardio.formstack.com/forms/eacvi_2025_call_for_sessions #cardiosky
Reposted by Amir Hasan
Hello #Medsky #CardioSky
The ESC is now on Bluesky🙂
We aim to bring you here the latest in cutting-edge cardiovascular science, from all ESC resources, including the successful #ESCTVToday CV news programme. We equally aim to bring you updates from all ESC communities and to bring you altogether.
The ESC is now on Bluesky🙂
We aim to bring you here the latest in cutting-edge cardiovascular science, from all ESC resources, including the successful #ESCTVToday CV news programme. We equally aim to bring you updates from all ESC communities and to bring you altogether.
December 12, 2024 at 11:27 AM
Hello #Medsky #CardioSky
The ESC is now on Bluesky🙂
We aim to bring you here the latest in cutting-edge cardiovascular science, from all ESC resources, including the successful #ESCTVToday CV news programme. We equally aim to bring you updates from all ESC communities and to bring you altogether.
The ESC is now on Bluesky🙂
We aim to bring you here the latest in cutting-edge cardiovascular science, from all ESC resources, including the successful #ESCTVToday CV news programme. We equally aim to bring you updates from all ESC communities and to bring you altogether.
Reposted by Amir Hasan
